🍎 Randomized controlled trial finds a whole food diet induces remission in children and young adults with mild to moderate #CrohnsDisease and is more tolerable than exclusive enteral nutrition. 🔗 https://t.co/5LzFmWp0tv

One of the greatest sporting performances I’ve ever witnessed

REPREVIO results in print for vedo in postop recurrence in Crohn's.

Extremely grateful to @GuildConference and @UofTGastroHep for the opportunity to learn, network and make new friends. See you soon!

How to write a grant? 1. Write it for the reviewer, not you, the applicant. 2. Communicate in stories. 3. Make your story cohesive—leave no puzzling gaps. 4. Make your story resonate to keep the reviewer reading. 5. Accept chance and noise in peer-review. https://t.co/wHZ065DNlm

Vedolizumab to prevent postop recurrence in #CD within 4w of surgery IV vedolizumab (300 mg) or placebo at weeks 0, 8, 16, and 24 @pilarnos @silvio_silvio75 @alearmuzzi @PeyrinBiroulet @LancetGastroHep https://t.co/jAVcQP9Pq5

🚨 New Article Alert 🚨 Researchers point out that the human milk-derived peptide drives rapid regulation of macrophage inflammation responses in the neonatal intestine. 🔗 https://t.co/MX8m1iS9iS

Gut bacteria essential to supporting our health are stably correlated with each other. Our Cell paper develops a new method for identifying the Core Microbiome: A core microbiome signature as an indicator of health

🚨New Paper Alert🚨 Our new #microbiome research, co-led with @LiatShenhav, published today in @CellCellPress! We show that #breastfeeding "paces" gut & nasal microbiome development to prevent #asthma in the @CHILDSTUDY. #Tweetorial 🧵 https://t.co/eeHSLIdw9Q

New research - Choy et al Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial https://t.co/UyrxUIahxb #IBD #GITwitter @DrMattChoy @DrChrisLi

SickKids scientists locate a novel, self-repairing recycling system ♻️ that helps keep mitochondria healthy – a finding that could help diagnosis/treatment of fatty liver disease, cancer + more. @Nature @NicolaJGI @JohnsHopkins @TheCrick @CIHR_IRSC ⬇ ⬇

Congrats to @cjketc2 & Dr. Khan on your new role with @AGA_Gastro! Meet all 10 fellows selected as our 2024-2025 editorial fellows:

https://t.co/wurl1wp7ta

A microbial community-scale metabolic modelling approach to design personalized dietary, #prebiotic and #probiotic interventions for optimizing SCFA production in the https://t.co/OvHq9Yvjbz improve health @NatureMicrobiol

Nice study. A validated lipidomic signature/biomarker of just two lipids in pediatric IBD: lactosyl ceramide and phosphatidylcholine. https://t.co/Z97w1UH2s6 Anyone else remember that there was a phase III study of phosphatidylcholine in UC that was terminated? #pediatricIBD

thank you for the award @ASGEendoscopy and @DDWMeeting, @jmosko29 and I are honoured

Human milk oligosaccharide 2’-fucosyllactose protects against high-fat diet-induced obesity by changing intestinal mucus production, composition and degradation linked to changes in gut microbiota and faecal proteome profiles in mice ⁦⁦@Gut_BMJ⁩

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease | medRxiv

Our June issue is out now at https://t.co/bK6A0hWoAC! Content: management of IBS, loss of response to anti-TNF in Crohn’s, HCC surveillance in Africa, the environmental impact of gastroenterology, liver transplant for ACLF, MASLD, viral hepatitis + more #GITwitter #LiverTwitter

Assuming no increase in tri-council/CFI funding today and 2.5% inflation rate out to 2027, here's what real funding to the Councils+ CFI looks like on a 25-year + perspective: